INOVIO PHARMACEUTICALS, INC. has historically generated modest revenue, with top-line figures rising slowly from $2.5 million in 2014 to $8.8 million in 2017, driven primarily by collaborations and licensing agreements. The firm's breakthrough DNA medicine platform paired with its CELLECTRA device remains promising but faces regulatory complexity due to the novelty of drug-device combination products. Despite ongoing development of candidates such as INO-3107 for HPV-related diseases, the company incurs steep operating losses, totaling about $87 million in 2025, while burning substantial cash flow. Liquidity constraints present a key risk with a going concern qualification noted beyond Q2 2026, as continued operations depend on successful clinical progress and new capital raises. Capital allocation has focused on financing R&D and warrant issuances rather than dividends or buybacks, reflecting INOVIO's developmental stage and financial pressures.